Mediwhale Revenue and Competitors
Estimated Revenue & Valuation
- Mediwhale's estimated annual revenue is currently $5M per year.
- Mediwhale's estimated revenue per employee is $131,368
- Mediwhale's total funding is $36M.
Employee Data
- Mediwhale has 38 Employees.
- Mediwhale grew their employee count by 90% last year.
Mediwhale's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO, Co-founder | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Medical Officer, Co-founder | Reveal Email/Phone |
4 | Chief Product Officer, Co-founder | Reveal Email/Phone |
5 | Chief Operation Officer | Reveal Email/Phone |
6 | COO | Reveal Email/Phone |
7 | Chief Product Officer | Reveal Email/Phone |
8 | Head Medical Affairs | Reveal Email/Phone |
9 | Head Korea Business | Reveal Email/Phone |
10 | Head Clinical Operations | Reveal Email/Phone |
Mediwhale Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 39 | 8% | $13.9M | N/A |
#2 | $8.2M | 57 | 0% | $10.2M | N/A |
#3 | $7.8M | 53 | 18% | $21.8M | N/A |
#4 | $5M | 38 | 90% | $36.3M | N/A |
What Is Mediwhale?
Mediwhale is the AI-empowered health diagnostics company that uses non-invasive retina scans to help prevent heart and kidney diseases. Mediwhale’s Reti-Intelligence suite of services uses deep learning algorithms to detect disease risks even before symptoms appear. Mediwhale has been dedicated to making preventative care more affordable, accessible, safe, and convenient since being founded in 2016 in South Korea. Mediwhale has product approvals in 8 territories in Europe and Asia (including EU, UK, Australia, Korea), and is under FDA approval.
keywords:N/A$36M
Total Funding
38
Number of Employees
$5M
Revenue (est)
90%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.3M | 38 | 12% | N/A |
#2 | $5M | 39 | 8% | $14M |
#3 | $6.4M | 39 | -5% | N/A |
#4 | $4.6M | 40 | -37% | N/A |
#5 | $8.9M | 41 | -15% | N/A |